Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 13/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25408033 | 1.00 | SPPL2A (0.54) | SPPL2ADRD2EPHX2KMT2AL3MBTL1 | |
| SCHEMBL26847743 | 1.00 | SPPL2A (0.54) | SPPL2ADRD2EPHX2KMT2AL3MBTL1 | |
| SCHEMBL26848107 | 0.86 | SPPL2A (0.64) | SPPL2ADRD2XIAP | |
| SCHEMBL26847753 | 0.84 | SPPL2A (0.51) | SPPL2AKMT2AL3MBTL1NFKB1NFKB2 | |
| SCHEMBL26847752 | 0.84 | SPPL2A (0.51) | SPPL2AKMT2AL3MBTL1NFKB1NFKB2 | |
| SCHEMBL26847750 | 0.84 | SPPL2A (0.51) | SPPL2AKMT2AL3MBTL1NFKB1NFKB2 | |
| SCHEMBL26848115 | 0.84 | SPPL2A (0.63) | SPPL2ADRD2XIAP | |
| SCHEMBL26848124 | 0.84 | SPPL2A (0.63) | SPPL2ADRD2XIAP | |
| SCHEMBL26848220 | 0.83 | SPPL2A (0.70) | SPPL2AXIAP | |
| SCHEMBL25408370 | 0.83 | SPPL2A (0.60) | SPPL2AKMT2AXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | INCYTE CORPORATION | 2025-08-21 | — | — | US | disclosed |
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | SPPL2A 1/4885DRD2 4416/4885EPHX2 2441/4885 |
| US-20250263416-A1 | SPPL2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | SPPL2A 1/4885DRD2 4612/4885EPHX2 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.